Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer - Concepedia

Concepedia

Publication | Open Access

Targeting the PI3K and MAPK pathways to improve response to HER2-targeted therapies in HER2-positive gastric cancer

DOI Full Paper Access

37

Citations

47

References

2021

Year

M. Janusz Mezynski, Angela M. Farrelly, Mattia Cremona, Aoife Carr, Clare Morgan, Julie Workman, Paul A. Armstrong, Jennifer McAuley, Stephen F. Madden, Joanna Fay,

Journal of Translational Medicine

Abstract

PI3K or MEK inhibition alone or in combination with anti-HER2 therapy may represent an improved treatment strategy for some patients with HER2-positive GC, and warrants further investigation in a clinical trial setting.

References

	Year	Citations

Page 1